Catalytic antibodies to factor VIII in haemophilia A

Blood Coagulation and Fibrinolysis

Volumn 14, Issue SUPPL. 1, 2003, Pages

  Lacroix Desmazes, Sébastien ^a   Kazatchkine, Michel D ^a   Kaveri, Srini V ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Catalytic antibodies; Factor VIII; Factor VIII inhibitors; Haemophilia A

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CATALYTIC ANTIBODY; IMMUNOGLOBULIN G; PROCOAGULANT; VON WILLEBRAND FACTOR;

CONFERENCE PAPER; ENZYME ACTIVE SITE; HEMOPHILIA A; HUMAN; HYDROLYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; SEROPREVALENCE; STEREOSPECIFICITY; X CHROMOSOME LINKED DISORDER;

ANIMALS; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; BINDING SITES, ANTIBODY; FACTOR VIII; HEMOPHILIA A; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN G; ISOANTIBODIES; MICE; SUBSTRATE SPECIFICITY;

EID: 0042125323     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200306001-00008     Document Type: Conference Paper

References (20)

1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 33:594-598.
2. de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, de Biasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with pure plasma derived concentrates. Thromb Haemost 1994; 71:544-547.
3. Fulcher CA. Immunochemistry of factor VIII:C inhibitors antibodies. Am J Med 1991; 91:6S-8S.
4. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards non-functional determinants and do not exhibit isotypic restriction. Blood 1993; 82:2452-2461.
5. Fulcher CA, Lechner K, De Graaf Mahoney S. Immunoblot analysis shows changes in FVIII inhibitor chain specificity in FVIII inhibitor patients over time. Blood 1988; 72:1348-1356.
6. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978-1984.
7. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69:240-246.
8. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92:136-142.
9. Saenko EL, Shima M, Gilbert GB, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271:274424-274431.
10. Fulcher CA, De Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82:7728-7732.
11. Kazatchkine MD, Sultan Y, Burton-Kee EJ, Mowbray JF. Circulating immune complexes containing anti-FVIII antibodies in multitransfused patients with haemophilia A. Clin Exp Immunol 1980; 39:315-320.
12. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, et al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5:1044-1047.
13. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science 1986; 234:1566-1570.
14. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 1989; 244:1158-1162.
15. Gololobov GV, Chernova EA, Schourov DV, Smirnov IV, Kudelina IA, Gabibov AG. Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: application of the flow linear dichroism technique. Proc Natl Acad Sci USA 1995; 92:254-257.
16. Li L, Paul S, Tyutyulkova S, Kazatchkine MD, Kaveri S. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 1995; 154:3328-3332.
17. Thiagarajan P, Dannenbring R, Matsuura K, Tramontano A, Gololobov G, Paul S. Monoclonal antibody light chain with prothrombinase activity. Biochemistry 2000; 39:6459-6465.
18. Li L, Kalaga R, Kaveri S, Paul S. Methods of measuring thyroglobulin and peptide-methylcoumarinamide hydrolysis by autoantibodies. In: Paul S. (editor): Methods in molecular biology: antibody engineering protocols. Vol. 51. Totowa, NJ: Humana Press Inc.; 1996. p. 417.
19. Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346:662-667.
20. Moreau A, Lacroix-Desmazes S, Stieltjes N, Saenko E, Kaveri SV, d'Oiron R et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity, are present in the plasma of non-responder patients with severe hemophilia A and healthy blood donors. Blood 2000, 95:3435.